國家衛生研究院 NHRI:Item 3990099045/10946
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 857823      線上人數 : 836
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/10946


    題名: Identification of genetic loci for treatment response of selective serotonin reuptake inhibitors on empirically defined depression syndromal factors
    作者: Kuo, PH;Chen, YT;Kao, CF;Yang, AC;Tsai, SJ;Liu, YL
    貢獻者: Center for Neuropsychiatric Research
    摘要: Background: Major depressive disorder (MDD) is a complex and multifactorial disorder with heterogeneous syndromal presentations. Patients ’ response to commonly prescribed selective serotonin reuptake inhibitors (SSRIs) varies across individuals and symptoms. Certain genetic variants may modify the effects of SSRIs treatment on different symptoms. Methods: We recruited patients with a diagnosis of MDD from two central hospitals in Taiwan, who were treated with escitalopram (38.5 %), paroxetine (38.5%), fluoxetine (18.3%), and citalopram (4.8%). Depression severity was rated using the 21-item Hamilton Rating Scale for Depression (HRSD) in all participants, with a minimum score of 14 at baseline for inclusion. Patients were assessed repeatedly at week 2, 4, and 8. All participants were genotyped using Illumina Human Omni Express Exome Bead Chips in the International SSRI Pharmacogenomics Consortium. After quality controls, 421 patients (mean age of 43.7 years and 71% of females) with 4,241,701 genotyped and well-imputed SNPs were retained for analysis. We first performed exploratory factor analysis to identify latent syndromal factors for baseline HRSD. Treatment response was de fined for two variables: score change (score difference between baseline and week-4, divided by the total score in each factor – scaling to range between 0-1), and binary response ( ⩾ 50% score reduction from baseline to week-4). Linear and logistic regression models were used for association testing while adjusted for age and sex. Results: We obtained six empirically derived factors for HRSD, namely sleep, core, anxiety, somatization, psychomotor, and energy. The degree of improvement in syndromal severity at week-4 was ranged from 33% (energy) to 70% (psychomotor). No markers reached genome-wide significance level. Nevertheless, several loci showed suggestive signals with p-value o 5 10-6, 43 for score change and 12 for response. The most significant marker was rs2938029 (P = 6.4 10-7) in NRXN3 for anxiety score change. A number of known genes were mapped for their associations with syndrome improvement in different factors, such as IL7R and MORN3 (core), RARB and SLC5A8 (psychomotor), KCNIP4 (energy) for score change, and SUCLG2 (anxiety), C8A and POC1B (psychomotor) for binary response. Interestingly, loci in or near (15kb away) an enhancer (ENSR00002058236) were associated with sleep factor in both score change and response outcome variables. Discussion: We found several genes that might affect treatment response of different empirically de fined syndromal factors among SSRIs treated depression patients. Further replication studies are needed to con firm our findings in other populations.
    日期: 2017-10
    關聯: European Neuropsychopharmacology. 2017 Oct;27:S390.
    Link to: http://dx.doi.org/10.1016/j.euroneuro.2016.09.426
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0924-977X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000413847300055
    顯示於類別:[劉玉麗] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000413847300055.pdf42KbAdobe PDF330檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋